Clinical Responses to CAR.CD30-T Cells in Patients with CD30+ Lymphomas Relapsed after Multiple Treatments Including Brentuximab Vedotin

Conclusions:We show that CD30.CAR-Ts combined with lymphodepletion with benda/ flu are safe and at 2 x 108 CAR T cells/m2 demonstrate excellent antitumor activity for pts with r/r CD30+ lymphomas. We also find that the addition of flu is critical for enhancing cytokines important for T cell growth and persistence. Finally, we demonstrate a significant PFS advantage in pts with r/r CD30+ lymphoma who received the highest dose level combined with benda and flu.DisclosuresGrover: Seattle Genetics: Consultancy. Park: G1 Therapeutics: Consultancy; Gilead: Speakers Bureau; Seattle Genetics: Research Funding; Teva: Research Funding; Rafael Pharma: Consultancy; BMS: Consultancy; BMS: Research Funding; Seattle Genetics: Speakers Bureau; Teva: Consultancy; Takeda: Research Funding. Dittus: Seattle Genetics: Consultancy. Serody: Merck: Research Funding.

Source: Blood - November 21, 2018 Category: Hematology Authors: Grover, N. S., Park, S. I., Ivanova, A., Eldridge, P., McKay, K., Cheng, C. J. A., Laing, S., Covington, D., West, J., Sharf, S. E., Morrison, J. K., Scott, S., Crecelius, E., Shelley, D., Alexander, M., Buchanan, F. B., Kassam, E. H., McElfresh, M., Pint Tags: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies: Immunotherapy and Targeted Strategies Source Type: research